Deerfield Management Company L.P. Series C Grows Stake in Phibro Animal Health Co. (NASDAQ:PAHC)

Deerfield Management Company L.P. Series C lifted its stake in shares of Phibro Animal Health Co. (NASDAQ:PAHC) by 102.4% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 25,164 shares of the company’s stock after purchasing an additional 12,731 shares during the period. Deerfield Management Company L.P. Series C’s holdings in Phibro Animal Health were worth $422,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Jacobs Levy Equity Management Inc. lifted its position in shares of Phibro Animal Health by 56.0% in the first quarter. Jacobs Levy Equity Management Inc. now owns 79,667 shares of the company’s stock valued at $1,030,000 after acquiring an additional 28,584 shares in the last quarter. Illinois Municipal Retirement Fund lifted its position in shares of Phibro Animal Health by 7.2% in the first quarter. Illinois Municipal Retirement Fund now owns 11,430 shares of the company’s stock valued at $148,000 after acquiring an additional 765 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Phibro Animal Health by 32.8% in the first quarter. Acadian Asset Management LLC now owns 675,207 shares of the company’s stock valued at $8,726,000 after acquiring an additional 166,776 shares in the last quarter. Sofinnova Investments Inc. purchased a new position in shares of Phibro Animal Health in the second quarter valued at approximately $3,975,000. Finally, BNP Paribas Financial Markets lifted its position in shares of Phibro Animal Health by 13.5% in the first quarter. BNP Paribas Financial Markets now owns 83,179 shares of the company’s stock valued at $1,076,000 after acquiring an additional 9,892 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Insiders Place Their Bets

In other Phibro Animal Health news, Director E Thomas Corcoran bought 5,000 shares of the business’s stock in a transaction on Wednesday, September 4th. The stock was bought at an average price of $20.02 per share, with a total value of $100,100.00. Following the completion of the purchase, the director now directly owns 25,000 shares in the company, valued at $500,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 50.06% of the stock is owned by insiders.

Phibro Animal Health Stock Performance

Shares of Phibro Animal Health stock opened at $22.07 on Friday. Phibro Animal Health Co. has a one year low of $9.40 and a one year high of $22.76. The company has a market cap of $893.90 million, a price-to-earnings ratio of 68.97, a PEG ratio of 1.77 and a beta of 0.52. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.64 and a current ratio of 2.94. The business’s 50 day moving average price is $19.68 and its 200 day moving average price is $17.13.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, August 28th. The company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.07. Phibro Animal Health had a return on equity of 18.08% and a net margin of 0.24%. The firm had revenue of $273.16 million for the quarter, compared to the consensus estimate of $262.44 million. On average, research analysts predict that Phibro Animal Health Co. will post 1.44 EPS for the current year.

Phibro Animal Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 25th. Shareholders of record on Wednesday, September 4th were paid a dividend of $0.12 per share. The ex-dividend date of this dividend was Wednesday, September 4th. This represents a $0.48 annualized dividend and a yield of 2.17%. Phibro Animal Health’s dividend payout ratio (DPR) is 150.00%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on PAHC. JPMorgan Chase & Co. began coverage on Phibro Animal Health in a research report on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 target price on the stock. Bank of America raised their target price on Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research report on Friday, August 30th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $15.00.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.